Apricus Biosciences IncFind Ratings Reports
APRICUS BIOSCIENCES INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. APRICUS BIOSCIENCES INC has very weak liquidity. Currently, the Quick Ratio is 0.23 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity decreased from the same period a year ago, despite already having very weak liquidity to begin with. This would indicate deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has increased by 24.41% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY16||Q4 FY15|
|Net Sales ($mil)||0.36||2.63|
|Net Income ($mil)||-0.3||-2.33|
|Balance Sheet||Q4 FY16||Q4 FY15|
|Cash & Equiv. ($mil)||2.09||4.17|
|Total Assets ($mil)||4.7||7.86|
|Total Debt ($mil)||6.65||9.48|
|Profitability||Q4 FY16||Q4 FY15|
|Gross Profit Margin||99.44||-126.85|
|Return on Assets||-158.14||-242.17|
|Return on Equity||0.0||0.0|
|Debt||Q4 FY16||Q4 FY15|
|Share Data||Q4 FY16||Q4 FY15|
|Shares outstanding (mil)||7.73||5.04|
|Div / share||0.0||0.0|
|Book value / share||-0.97||-1.97|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||477152.0||1348160.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount.
|APRI NM||Peers 87.33||APRI NM||Peers 19.75|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
APRI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
APRI's P/CF is negative making the measure meaningless.
|APRI 16.83||Peers 15.90||APRI NA||Peers 0.73|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
APRI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|APRI NM||Peers 13.78||APRI 56.85||Peers -3.58|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
APRI's P/B is negative making this valuation measure meaningless.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
APRI is expected to have an earnings growth rate that significantly exceeds its peers.
|APRI 1.36||Peers 14.05||APRI 19.09||Peers 4.04|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
APRI is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
APRI has a sales growth rate that significantly exceeds its peers.